Determination of airborne and surface contamination with cyclophosphamide at the Masaryk Memorial Cancer Institute, Brno, Czech Republic
Authors:
Lucie Gorná 1; Pavel Odráška 1,2; Lenka Doležalová 1; Pavel Piler 2; Michal Oravec 2; Luděk Bláha 1,2
Authors‘ workplace:
Masarykův onkologický ústav, Brno
1; Masarykova univerzita v Brně, Přírodovědecká fakulta, RECETOX (Výzkumné centrum pro toxické látky v prostředí)
2
Published in:
Čes. slov. Farm., 2011; 60, 25-31
Category:
Original Articles
Overview
Manipulation with cytotoxic drugs (CDs) during the preparation and administration of chemotherapy to cancer patients can potentially lead to contamination of working areas and consequently to occupational exposure of hospital staff. This study aimed to assess the potential of inhalation and dermal contact with CDs. For this purpose, distribution of the marker drug (cyclophosphamide, CP) in the working environment of the Masaryk Memorial Cancer Institute (Czech Republic) was studied. The study determined airborne and surface contamination of the hospital pharmacy and the outpatient clinic. Determination of airborne contamination was based on active stationary sampling of air using a PTFE filter, an impinger filled with distilled water and two solid sorbent tubes (Anasorb 708 and Strata-X) as sampling devices. Surface contamination was determined by the wipe sampling method. The airborne contamination was rare and the concentrations were many times lower than the maximal value calculated from the vapour pressure (0.36 mg/m3 at 20 °C). Detectable airborne CP was found in Strata-X samples collected at the outpatient clinic (n = 5, all samples positive at concentrations from 0.3 to 4.3 ng/m3). Surface contamination was determined at 75% of wipe samples (n = 65) with a median concentration of 750 ng/m2. In conclusion, inhalation of CDs seems to be of low importance at our hospital, which is up to the standard specified by current legislation (drug preparation performed in a clean room equipped with negative pressure isolators). The main proportion of contamination was present on the surfaces at all workplaces studied. Consequently, attention should be given to the elimination of the sources of surface contamination and to the prevention of dermal contact with contaminated material.
Key word:
cytotoxic drugs – cyclophosphamide – occupational exposure – surface contamination – airborne contamination
Sources
1. Baker, G. L., Kahl, L. E., Zee, B. C., Stolzer, B. L., Agarwal, A. K., Medsger, T. A.: Malignancy following treatment of rheumatoid-arthritis with cyclophosphamide – long-term case-control follow-up study. Am. J. Med. 1987; 83, 1–9.
2. Fuchs, J., Hengstler, J. G., Jung, D., Hiltl, G., Konietzko, J., Oesch, F.: DNA damage in nurses handling antineoplastic agents. Mutation Research/ Genetic Toxicology 1995; 342, 17–23.
3. Krstev, S., Perunicic, B. and Vidakovic, A.: Work practice and some adverse health effects in nurses handling antineoplastic drugs. Med. Lav. 2003; 94, 432–439.
4. Hemminki, K., Kyyronen, P., Lindbohm, M. L.: Spontaneous–abortions and malformations in the offspring of nurses exposed to anesthetic-gases, cytostatic drugs, and other potential hazards in hospitals, based on registered information of outcome. J. Epidemiol. Community Health 1985; 39, 141–147.
5. Greene, M. H., Harris, E. L., Gershenson, D. M., Malkasian, G. D., Melton, L. J., Dembo, A. J., Bennett, J. M., Moloney, W. C., Boice, J. D.: Melphalan may be a more potent leukemogen than cyclophosphamide. Ann. Intern. Med. 1986; 105, 360–367.
6. Haas, J. F., Kittelmann, B., Mehnert, W. H., Staneczek, W., Mohner, M., Kaldor, J. M., Day, N. E.: Risk of leukemia in ovarian tumor and breast-cancer patients following treatment by cyclophosphamide. Br. J. Cancer 1987; 55, 213–218.
7. Kaldor, J. M., Day, N. E., Pettersson, F., Clarke, E. A., Pedersen, D., Mehnert, W., Bell, J., Host, H., Prior, P., Karjalainen, S., Neal, F., Koch, M., Band, P., Choi, W., Kirn, V. P., Arslan, A., Zaren, B., Belch, A. R., Storm, H., Kittelmann, B., Fraser, P., Stovall, M.: Leukemia following chemotherapy for ovarian-cancer. N. Engl. J. Med. 1990; 322, 1–6.
8. Sessink, P. J. M., Vandekerkhof, M. C. A., Anzion, R. B. M., Noordhoek, J., Bos, R. P.: Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians – is skin absorption an important exposure route. Arch. Environ. Health 1994; 49, 165–169.
9. Micoli, G., Turci, R., Arpellini, M., Minoia, C.: Determination of 5–fluorouracil in environmental samples by solid–phase extraction and high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B 2001; 750, 25–32.
10. Mason, H. J., Blair, S., Sams, C., Jones, K., Garfitt, S. J., Cuschieri, M. J., Baxter, P. J.: Exposure to antineoplastic drugs in two uk hospital pharmacy units. Ann. Occup. Hyg. 2005; 49, 603–610.
11. Kiffmeyer, T., Kube, C., Opiolka, S., Schmidt, K. G., Schoppe, G., Sessink, P. J. M.: Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: Implications for occupational safety. The Pharmaceutical Journal 2002; 268, 331–337.
12. Kromhout, H., Hoek, F., Uitterhoeve, R., Huijbers, R., Overmars, R. F., Anzion, R., Vermeulen, R.: Postulating a dermal pathway for exposure to anti–neoplastic drugs among hospital workers. Ann Occup Hyg 2000; 44, 551–560.
13. Fransman, W., Vermeulen, R., Kromhout, H.: Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int. Arch. Occup. Environ. Health 2005; 78, 403–412.
14. Sessink, P. J. M., Boer, K. A., Scheefhals, A. P. H., Anzion, R. B. M., Bos, R. P.: Occupational exposure to antineoplastic agents at several departments in a hospital – environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int. Arch. Occup. Environ. Health 1992; 64, 105–112.
15. Sessink, P. J. M., Timmersmans, J. L., Anzion, R. B. M., Bos, R. P.: Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil – determination of alpha-fluoro-beta-alanine in urine. J. Occup. Environ. Med. 1994; 36, 79–83.
16. Sessink, P. J. M., Cerna, M., Rossner, P., Pastorkova, A., Bavarova, H., Frankova, K., Anzion, R. B. M., Bos, R. P.: Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 1994; 309, 193–199.
17. Mader, R. M., Rizovski, B., Steger, G. G., Wachter, A., Kotz, R., Rainer, H.: Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch. Environ. Health 1996; 51, 310–314.
18. Nygren, O. and Lundgren, C.: Determination of platinum in workroom air and in blood and urine from nursing staff attending patients receiving cisplatin chemotherapy. Int. Arch. Occup. Environ. Health 1997; 70, 209–214.
19. Minoia, C., Turci, R., Sottani, C., Schiavi, A., Perbellini, L., Angeleri, S., Draicchio, F. and Apostoli, P.: Application of high performance liquid chromatography tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commun. Mass Spectrom. 1998; 12, 1485–1493.
20. NIOSH: Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings. NIOSH Alert. Cincinnati, OH: NIOSH. 2004; 1–61.
21. ASHP: Guidelines on handling hazardous drugs. Am. J. Health. Syst. Pharm. 2006; 63, 1172–1193.
22. ISOPP: Isopp standards of practice: Safe handling of cytotoxics. Journal of Oncology Pharmacy Practice 2007; 13(Suppl.), 1–81.
23. Doležalová, L., Odráška, P., Gorná, L., Kuta, J., Oravec, M., Prudilová, M., Vejpustková, R., Bláha, L.: Studium kontaminace pracovišť a profesionální expozice zdravotnických pracovníků zajišťujících přípravu a aplikaci protinádorových léčiv. Pracovní lékařství 2009; 61, 117–122.
24. Odráška, P., Gorná, L., Doležalová, L., Oravec, M., Kuta, J., Bláha, L.: Monitoring povrchové kontaminace cytotoxickými léčivy v nemocničních lékárnách české republiky. Čes. slov Farm. 2009; 58, 225–229.
25. Opiolka, S., Molter, W., Kiffmeyer, T., Goldschmidt, R., Schoppe, G., Schmidt, K. G.: Dampfdrucke von zytostatika. Gefahrstoffe Reinhaltung Der Luft 1999; 59, 443–444.
26. Connor, T. H., Shults, M., Fraser, M. P.: Determination of the vaporization of solutions of mutagenic antineoplastic agents at 23 and 37 ľC using a desiccator technique. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2000; 470, 85–92.
27. Larson, R. R., Khazaeli, M. B., Dillon, H. K.: A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents. Appl. Occup. Environ. Hyg. 2003; 18, 120–131.
28. Chafer-Pericas, C., Herraez-Hernandez, R., Campins-Falco, P.: Selective determination of trimethylamine in air by liquid chromatography using solid phase extraction cartridges for sampling. Journal of Chromatography A 2004; 1042, 219–223.
29. Tollback, J., Tamburro, D., Crescenzi, C., Carlsson, H.: Air sampling with empore solid phase extraction membranes and online single-channel desorption/liquid chromatography/mass spectrometry analysis: Determination of volatile and semi–volatile organophosphate esters. Journal of Chromatography A 2006; 1129, 1–8.
30. deWerk Neal, A., Wadden, R., Chiou, W.: Exposure of hospital workers to airborne antineoplastic agents. Am. J. Health Syst. Pharm. 1983; 40, 597–601.
31. Sessink, P. J. M., Wittenhorst, B. C. J., Anzion, R. B. M., Bos, R. P.: Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch. Environ. Health 1997; 52, 240–244.
32. McDevitt, J. J., Lees, P. S. J., McDiarmid, M. A.: Exposure of hospital pharmacists and nurses to antineoplastic agents. J. Occup. Environ. Med. 1993; 35, 57–60.
33. Doležalová, L., Odráška, P., Gorná, L., Prudilová, M., Vejpustková, R., Bláha, L.: Studie evaporace vybraných cytostatik a propustnosti ochranných rukavic v rámci výzkumu profesní zátěže zdravotnických pracovníků exponovaných cytotoxickým protinádorovým léčivům (projekt cyto). Klinická onkologie 2009; 22, 218–222.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2011 Issue 1
Most read in this issue
- On teaching the chemistry of pharmaceutical auxiliary substances within the framework of pharmaceutical education in the Czech and Slovak Republics
- Study on 99mTc-MAG3 and 99mTc-DMSA renal accumulation using in vitro cellular model
- Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection
- Determination of airborne and surface contamination with cyclophosphamide at the Masaryk Memorial Cancer Institute, Brno, Czech Republic